MIST Earnings

MIST reported its earnings on 2026-03-20, showcasing a revenue of 1.50M against an estimate of 75.08M, resulting in a -98% surprise. The EPS was -0.16, surpassing the expected -0.18 by 11.11%. The stock experienced a -20% price change on the earnings day and a -26.47% change over the next five days, reflecting market reactions to the results.

Following MIST's earnings announcement on 2026-03-20, the stock price moved by -20% on the day of the release. Over the subsequent five days, it saw a -26.47% change. Historically, MIST's stock price tends to shift by an average of -4.77% in the 10 days leading up to earnings and 3.37% in the 10 days following, providing insight into potential market.

For , analysts estimate MIST's annual revenue to reach , while the EPS is projected at 0.17. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MIST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MIST's stock price typically moves by -4.77% in the 10 days before its earnings and 3.37% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.17 and revenue of .

The earnings call presents a mixed picture. Financial performance shows increased expenses and net loss, raising concerns. However, the company has a strong cash position and positive milestone revenue. The Q&A reveals challenges in insurance coverage and reimbursement delays, but also highlights broad prescriber feedback and patient support systems. The lack of specific data on patient outcomes and reimbursement timelines adds uncertainty. While there are positive aspects, such as milestone revenue, the overall sentiment is tempered by the challenges and uncertainties, leading to a neutral stock price prediction.